

Toby A Eyre

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5569476/publications.pdf>

Version: 2024-02-01

113
papers

2,646
citations

230014

27
h-index

263392

45
g-index

115
all docs

115
docs citations

115
times ranked

3221
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of positron emission tomography - computed tomography status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplantation. <i>Haematologica</i> , 2023, 108, 785-796.	1.7	4
2	Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England. <i>British Journal of Cancer</i> , 2022, 126, 134-143.	2.9	10
3	Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper. <i>British Journal of Haematology</i> , 2022, 196, 864-870.	1.2	10
4	Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management. <i>Hematological Oncology</i> , 2022, 40, 129-159.	0.8	4
5	Therapeutic options for relapsed/refractory mantle cell lymphoma. <i>Blood</i> , 2022, 139, 666-677.	0.6	27
6	Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare). <i>Clinical Cancer Research</i> , 2022, 28, 603-608.	3.2	11
7	Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. <i>Blood</i> , 2022, 139, 2499-2511.	0.6	42
8	Guideline for the treatment of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2022, 197, 544-557.	1.2	12
9	Bone health and glucocorticoid-containing lymphoma therapy " a review of risk factors and preventative measures. <i>British Journal of Haematology</i> , 2022, 198, 431-442.	1.2	6
10	Outcome of COVID-19 in Patients With Mantle Cell Lymphoma" Report From the European MCL Registry. <i>HemaSphere</i> , 2022, 6, e0711.	1.2	7
11	New Directions for Mantle Cell Lymphoma in 2022. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 614-628.	1.8	14
12	Real-world experience with caplacizumab in the management of acute TTP. <i>Blood</i> , 2021, 137, 1731-1740.	0.6	93
13	Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia. <i>Blood</i> , 2021, 137, 2800-2816.	0.6	51
14	Development of a Conceptual Model of Chronic Lymphocytic Leukemia to Better Understand the Patient Experience. <i>Patient</i> , 2021, 14, 75-87.	1.1	4
15	Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. <i>British Journal of Haematology</i> , 2021, 193, 290-298.	1.2	32
16	Limited-stage diffuse large B-cell lymphoma: current management and challenges. <i>British Journal of Haematology</i> , 2021, 194, 508-517.	1.2	2
17	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. <i>Lancet</i> , The, 2021, 397, 892-901.	6.3	260
18	The use of frailty assessments in treating older adults with aggressive lymphomas. <i>British Journal of Haematology</i> , 2021, 194, 677-685.	1.2	13

#	ARTICLE	IF	CITATIONS
19	Frontline management of posttransplantation lymphoproliferative disorder in adult solid organ recipient patients – A British Society for Haematology Guideline. <i>British Journal of Haematology</i> , 2021, 193, 727-740.	1.2	16
20	Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2118-2124.	1.3	6
21	Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP. <i>Blood Advances</i> , 2021, 5, 2229-2236.	2.5	14
22	Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis. <i>British Journal of Haematology</i> , 2021, 194, 365-377.	1.2	13
23	Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review. <i>Blood Advances</i> , 2021, 5, 2426-2437.	2.5	24
24	A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETROidel). <i>British Journal of Haematology</i> , 2021, 194, 69-77.	1.2	13
25	Reduction in incidence of non- <i>COVID-19</i> respiratory virus infection amongst haematology inpatients following UK social distancing measures. <i>British Journal of Haematology</i> , 2021, 195, 194-197.	1.2	8
26	Interpretation of retrospective data evaluating high-dose methotrexate as central nervous system prophylaxis in diffuse large B-cell lymphoma; caution required. <i>American Journal of Hematology</i> , 2021, 96, E338-E339.	2.0	5
27	<i>COVID-19</i> in patients with CLL: improved survival outcomes and update on management strategies. <i>Blood</i> , 2021, 138, 1768-1773.	0.6	53
28	A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma. <i>BMC Cancer</i> , 2021, 21, 851.	1.1	2
29	A comprehensive approach to therapy of haematological malignancies in older patients. <i>Lancet Haematology</i> , 2021, 8, e840-e852.	2.2	17
30	A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma. <i>HemaSphere</i> , 2021, 5, e656.	1.2	6
31	Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study. <i>Lancet Haematology</i> , 2021, 8, e912-e921.	2.2	32
32	High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients. <i>Blood</i> , 2021, 138, 181-181.	0.6	14
33	Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2021, 138, 381-381.	0.6	8
34	Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2021, 138, 391-391.	0.6	8
35	Another disappointment in treating relapsed, refractory high-risk aggressive B-cell lymphomas. <i>British Journal of Haematology</i> , 2020, 188, 202-204.	1.2	2
36	The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 918-923.	1.2	19

#	ARTICLE	IF	CITATIONS
37	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. <i>Blood</i> , 2020, 136, 1134-1143.	0.6	248
38	What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 923-939.	0.9	1
39	Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery. <i>Blood Advances</i> , 2020, 4, 3586-3593.	2.5	36
40	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. <i>Blood Advances</i> , 2020, 4, 3977-3989.	2.5	55
41	Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4337-4346.	2.5	11
42	Prognostication in Richter syndrome: context is everything. <i>British Journal of Haematology</i> , 2020, 190, 811-812.	1.2	0
43	Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review. <i>Haematologica</i> , 2020, 105, 1914-1924.	1.7	50
44	Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care. <i>Haematologica</i> , 2020, 105, e474-479.	1.7	10
45	Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy. <i>European Journal of Haematology</i> , 2020, 105, 476-483.	1.1	26
46	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. <i>Clinical Cancer Research</i> , 2020, 26, 3589-3596.	3.2	80
47	Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. <i>Haematologica</i> , 2020, 106, 284-287.	1.7	8
48	The investigation and management of follicular lymphoma. <i>British Journal of Haematology</i> , 2020, 191, 363-381.	1.2	14
49	Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients. <i>PLoS ONE</i> , 2020, 15, e0229469.	1.1	7
50	Efficacy of Râ€BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. <i>British Journal of Haematology</i> , 2020, 189, 684-688.	1.2	43
51	Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival. <i>British Journal of Haematology</i> , 2020, 190, 394-404.	1.2	27
52	DPACEâ€based chemotherapy in the era of myeloma novel agents: A UK multicentre study. <i>European Journal of Haematology</i> , 2020, 105, 231-233.	1.1	2
53	Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia. <i>Blood Advances</i> , 2020, 4, 525-529.	2.5	8
54	Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large Bâ€cell lymphoma of the central nervous system â€ an international study of feasibility and efficacy in routine clinical practice. <i>British Journal of Haematology</i> , 2020, 189, 879-887.	1.2	41

#	ARTICLE	IF	CITATIONS
55	LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2020, 136, 8-10.	0.6	5
56	Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE). <i>Blood</i> , 2020, 136, 19-22.	0.6	0
57	A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL. <i>Hematological Oncology</i> , 2019, 37, 352-359.	0.8	18
58	Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 207-218.	1.2	17
59	The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease. <i>BMC Cancer</i> , 2019, 19, 471.	1.1	19
60	Standard alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity. <i>British Journal of Haematology</i> , 2019, 187, 185-194.	1.2	49
61	Efficacy of R-GCVP in patients with late relapse of diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2019, 186, e191-e195.	1.2	0
62	Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. <i>Clinical Cancer Research</i> , 2019, 25, 4264-4270.	3.2	61
63	Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly <sc>DLBCL</sc> patients treated with R<sc>CHOP</sc>. <i>British Journal of Haematology</i> , 2019, 186, e94-e98.	1.2	10
64	Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age. <i>Journal of Internal Medicine</i> , 2019, 285, 681-692.	2.7	31
65	Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post<sc>BCR</sc> inhibitor setting: a <sc>UK</sc> wide analysis. <i>British Journal of Haematology</i> , 2019, 185, 656-669.	1.2	53
66	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. <i>Blood Advances</i> , 2019, 3, 1568-1573.	2.5	26
67	Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. <i>Haematologica</i> , 2019, 104, e68-e71.	1.7	97
68	A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer. <i>Cancer</i> , 2019, 125, 99-108.	2.0	17
69	Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. <i>Blood</i> , 2019, 133, 299-305.	0.6	69
70	Idelalisib^Rrituximab induces durable remissions in <i>TP53</i> disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme. <i>British Journal of Haematology</i> , 2019, 184, 667-671.	1.2	19
71	Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies. <i>Blood</i> , 2019, 134, 502-502.	0.6	4
72	Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies. <i>Blood</i> , 2019, 134, 1756-1756.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Ibrutinib at First Relapse for Mantle Cell Lymphoma: A United Kingdom Real World Analysis of Outcomes in 169 Patients. <i>Blood</i> , 2019, 134, 3993-3993.	0.6	3
74	R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy. <i>Blood</i> , 2019, 134, 3989-3989.	0.6	5
75	Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents. <i>Blood</i> , 2019, 134, 3321-3321.	0.6	2
76	Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study. <i>Blood</i> , 2019, 134, 3048-3048.	0.6	0
77	Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue): Cognitive Debriefing in Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 4777-4777.	0.6	1
78	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , 2018, 103, 1209-1217.	1.7	30
79	Results of a multicentre <sc>UK</sc>-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma. <i>British Journal of Haematology</i> , 2018, 181, 555-559.	1.2	13
80	Lessons from the INTERVAL study. <i>Lancet, The</i> , 2018, 391, 2605-2606.	6.3	0
81	Impact of Intended and Relative Dose Intensity of RCHOP in a Large, Consecutive Cohort of Elderly DLBCL Patients: No Difference in DFS for 70-80 Years Versus >80 Years and Idi Independently Predicts Survival. <i>Blood</i> , 2018, 132, 573-573.	0.6	1
82	Predictive biomarkers for disease sensitivity in lymphoma - the holy grail for HDAC inhibitors?. <i>Oncotarget</i> , 2018, 9, 37280-37281.	0.8	2
83	Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study. <i>Blood</i> , 2018, 132, 4759-4759.	0.6	1
84	An update for Richter syndrome " new directions and developments. <i>British Journal of Haematology</i> , 2017, 178, 508-520.	1.2	28
85	High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom. <i>Bone Marrow Transplantation</i> , 2017, 52, 1268-1272.	1.3	18
86	Results of a multicentre <sc>UK</sc>-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting. <i>British Journal of Haematology</i> , 2017, 179, 471-479.	1.2	20
87	Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia. <i>British Journal of Haematology</i> , 2017, 177, 486-491.	1.2	12
88	Acute monoblastic leukemia presenting with striking periorbital and periauricular infiltration. <i>Blood</i> , 2017, 129, 3396-3396.	0.6	0
89	Multiple myeloma in the very elderly patient: challenges and solutions. <i>Clinical Interventions in Aging</i> , 2016, 11, 423.	1.3	28
90	Results of a multicentre <sc>UK</sc>-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 896-904.	1.2	19

#	ARTICLE	IF	CITATIONS
91	Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients with <i>de novo</i> diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 487-491.	1.2	38
92	Diagnostic dilemmas of high-grade transformation (Richter's syndrome) of chronic lymphocytic leukaemia: results of the phase II National Cancer Research Institute CHOP-OR clinical trial specialist haematopathology central review. <i>Histopathology</i> , 2016, 69, 1066-1076.	1.6	36
93	NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome. <i>British Journal of Haematology</i> , 2016, 175, 43-54.	1.2	53
94	Characterization of Recurrent Mutations in Patient with a Richter Syndrome By Targeted Next Generation Sequencing. <i>Blood</i> , 2016, 128, 3200-3200.	0.6	4
95	A Dose-Escalation (DE) Study with Expansion Evaluating Safety, Pharmacokinetics and Efficacy of the Novel, Balanced PI3K/mTOR Inhibitor PQR309 in Patients with Relapsed or Refractory Lymphoma. <i>Blood</i> , 2016, 128, 5893-5893.	0.6	5
96	Acalabrutinib Monotherapy in Patients with Richter Transformation from the Phase 1/2 ACE-CL-001 Clinical Study. <i>Blood</i> , 2016, 128, 60-60.	0.6	40
97	A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2015, 170, 886-890.	1.2	27
98	Incidence, management, and outcome of high-grade transformation of nodular lymphocyte predominant hodgkin lymphoma: Long-term outcomes from a 30-year experience. <i>American Journal of Hematology</i> , 2015, 90, E103-10.	2.0	31
99	Single arm NCRI phase II study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter's syndrome. <i>BMC Cancer</i> , 2015, 15, 52.	1.1	9
100	Immune checkpoint inhibition in lymphoid disease. <i>British Journal of Haematology</i> , 2015, 170, 291-304.	1.2	20
101	Management and controversies of classical Hodgkin lymphoma in pregnancy. <i>British Journal of Haematology</i> , 2015, 169, 613-630.	1.2	28
102	Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies. <i>British Journal of Haematology</i> , 2014, 166, 336-351.	1.2	40
103	Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease. <i>European Journal of Haematology</i> , 2014, 93, 455-468.	1.1	38
104	T-cell/histiocyte-rich large B-cell lymphoma - transformation of Nodular lymphocyte predominant Hodgkin lymphoma in the bone marrow. <i>European Journal of Haematology</i> , 2014, 92, 550-551.	1.1	2
105	Dutcher bodies: cytoplasmic inclusions within the nucleus. <i>British Journal of Haematology</i> , 2014, 166, 946-947.	1.2	9
106	Partial engraftment following plerixafor rescue after failed sibling donor peripheral blood stem cell harvest. <i>Transfusion</i> , 2014, 54, 1231-1234.	0.8	5
107	Gemcitabine-induced large vessel vasculitis demonstrated by PET CT: a rare, important side effect. <i>International Journal of Hematology</i> , 2014, 99, 798-800.	0.7	12
108	Mumps virus encephalomyelitis in a 19-year old male patient with an undefined severe combined immunodeficiency post-haematopoietic bone marrow transplantation: A rare fatal complication. <i>Journal of Clinical Virology</i> , 2013, 57, 165-168.	1.6	4

#	ARTICLE	IF	CITATIONS
109	Interventions to Reduce Wrong Blood in Tube Errors in Transfusion: A Systematic Review. <i>Transfusion Medicine Reviews</i> , 2013, 27, 197-205.	0.9	22
110	Extranodal <sc>NK</sc>/<sc>T</sc> cell lymphoma, nasal type, presenting with meningeal infiltration in a <sc>C</sc>ucasian female. <i>British Journal of Haematology</i> , 2013, 163, 550-550.	1.2	2
111	Current treatment and future prospects for peripheral T-cell lymphoma. <i>Drugs of Today</i> , 2013, 49, 631.	0.7	2
112	Acute Isolated Transmural Neutropenic Gastritis. <i>Journal of Clinical Oncology</i> , 2012, 30, e1-e2.	0.8	3
113	An Unusual Cause of Anaemia of Chronic Disease: Lisinopril-Induced Chronic Inflammatory State. <i>Case Reports in Hematology</i> , 2011, 2011, 1-3.	0.3	1